“The increase in research and development expenses was primarily due to increases related to clinical trial costs, preclinical research and development expenses and employee expenses (primarily due to an increase in personnel).”
“If our operations were found to be in violation of any of these laws or any other governmental regulations that may apply to us, we could be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, additional regulatory oversight and integrity monitoring, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.”
“The increase in revenues was primarily due to acquisitions of $88.3 million, higher pricing of $49.4 million, and favorable impact of foreign currencies of $30.0 million, partially offset by lower organic volumes of $73.7 million.”